Last reviewed · How we verify

NCT05953948: ICMP

Effectiveness of Intelligent Case Manage Platform in Liver Transplant Recipients

ENROLLING BY INVITATION NA Last updated 20 March 2026
What this trial tests

NA trial testing Intelligent Case Manage Platform (ICMP) and self-management program in Liver Transplant Disorder in 333 participants. Enrolling by invitation.

Timeline
1 February 2025
Primary endpoint
31 December 2027
31 December 2027

Quick facts

Lead sponsorChang Gung University
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposeother
Enrollment333
Start date1 February 2025
Primary completion31 December 2027
Estimated completion31 December 2027
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Chang Gung University

Who can join

20 and older, any sex, with Liver Transplant Disorder or Self Efficacy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, quasi-experimental design, with an experimental group and a control group, will be created. The aims of this study are as follows: 1. Describe the self-management and information needs of liver transplant recipients, 2. Create content or modules related to the self-management of liver transplant recipients, 3. Build an intelligent case management platform, 4. Evaluate the usability of the platform, and 5. Conduct deep learning and examine the effects of the intelligent case management platform on self-efficacy, self-management, health outcomes, and health-related quality of life. Data will be collected at discharge (baseline data) and 1, 3, 6, 9, and 12 months after discharge. An estimated 133 patients will be involved in this experiment: 44 in the experimental group and 89 in the control group. Statistical package software (SPSS 22.0) will be used to analyze the data. A generalized estimation equation model will examine the differences in self-efficacy, self-management, and health-related quality of life between the experimental and control groups. Survival analysis and the Kaplan-Meier method will be used to analyze health outcomes, including hospital readmission, emergency visits, episodes of infection and rejection of organs, and death.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Transplant Disorder

Currently open trials in the same condition.

Other Chang Gung University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05953948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing